Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models
AACR 2023 -- Upwards of 50% of cancer patients will receive radiation during the course of their treatment, mostly through a fractionated dosing schedule. Labcorp Drug Development has a wealth of data across syngeneic models employing a single dose of focal radiation. To bolster this data set, fractionated dosing regimens were employed in the CT26, MC38, E.G7-OVA and EMT-6 models to compare response to bolus focal radiation therapy. These more translationally relevant dosing regimens produce moderate responses that more accurately reflect the clinical landscape and provide a more viable framework for interrogating rational combination strategies in preclinical development.